It was found that autophagy inhibition using a clinically available antimalarial agent, chloroquine, increased surface levels of MHC-I and anti-tumor T cell responses when combined with ICI therapy (anti-PD-1 and anti-CTLA4). The gene discussed is PDCD1; the disease is neoplasm.